Comparative Pharmacology
Head-to-head clinical analysis: ENDURONYL versus HYDROPANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENDURONYL versus HYDROPANE.
ENDURONYL vs HYDROPANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiazide diuretic that inhibits the Na+-Cl− symporter in the distal convoluted tubule, reducing sodium and chloride reabsorption and promoting diuresis.
Thiazide diuretic; inhibits sodium chloride cotransporter in distal convoluted tubule, increasing excretion of sodium and water, and reducing plasma volume.
ENDURONYL (methyclothiazide and deserpidine) is a fixed-dose combination antihypertensive. Typical adult dose: 1 tablet (methyclothiazide 5 mg / deserpidine 0.25 mg) orally once daily. Dose may be increased to 2 tablets once daily if needed.
50–100 mg orally once daily, maximum 200 mg daily
None Documented
None Documented
Terminal elimination half-life 10-15 hours; clinically, may require 3-5 days to reach steady state in hypertension management.
Terminal elimination half-life is approximately 8-15 hours in patients with normal renal function; may be prolonged in renal impairment.
Primarily renal excretion; ~50% unchanged, ~25% as deserpidine metabolites, 20% biliary-fecal.
Renal (approximately 50% as unchanged drug) and hepatic metabolism to inactive metabolites; fecal elimination accounts for about 10%.
Category C
Category C
Thiazide Diuretic + Rauwolfia Alkaloid
Thiazide Diuretic